Retzius-sparing technique independently predicts early recovery of urinary continence after robot-assisted radical prostatectomy.

Journal: Journal of robotic surgery
Published Date:

Abstract

Robot-assisted radical prostatectomy (RARP) is the conventional surgical treatment option for localised prostate cancer. We investigated factors which may be associated with recovery of early urinary continence (EUC), including the use of the Retzius-sparing technique (RS-RARP). From March 2018 to December 2018, 501 consecutive patients underwent RARP at our high-volume institution. Four hundred and thirty-one patients had complete follow-up data and were included in our analyses. EUC was defined as zero pad use and social urinary continence (SUC) was defined as ≤ 1 pad/24-h period at 3 months following surgery. Patient demographics and clinical factors such as age, body mass index (BMI), neurovascular bundle (NVB) sparing, RS-RARP operative technique and operating surgeon (consultant, trainee) were recorded. Median age was 64.0 years (IQR 57.0-69.0 years) with a median BMI of 27.0 (IQR 25.0-29.9). RS-RARP accounted for 59 of the 431 (13.7%) patients. 196 (45.5%), 142 (32.9%) and 86 (20.0%) received a bilateral, unilateral and nil NVB sparing, respectively. EUC was achieved by 241 patients (55.9%) and SUC was achieved in 339 (78.7%) patients. Multivariable logistic regression analysis suggests younger age (HR 1.04, 95% CI 1.01-1.07, p = 0.014) and RS-RARP technique (HR 2.19, 95% CI 1.15-4.16, p = 0.017) were independently associated with EUC at 3 months even after adjusting for BMI, external membranous urethral length and NVB sparing. Our results suggest that RS-RARP technique is independently predictive of EUC even after accounting for confounding factors. These findings should be further validated in a prospective or randomised trial.

Authors

  • Hassan Kadhim
    Department of Urology, Ipswich Hospital, Ipswich, UK.
  • Kar Mun Ang
    Department of Medicine, Queen Elizabeth Hospital, Woolwich, UK.
  • Wei Shen Tan
    Department of Urology, Yale School of Medicine, New Haven, CT, USA.
  • Arjun Nathan
    Urology Department, Addenbrooke's Hospital, Cambridge, UK. arjun.nathan.11@ucl.ac.uk.
  • Nicola Pavan
    Department of Urology, Cattinara Hospital, University of Trieste, Trieste, Italy.
  • Giorgio Mazzon
    Department of Urology, University College London Hospital, London, UK.
  • Omar Al-Kadhi
    Department of Urology, University College London Hospital, London, UK.
  • Gu Di
    Department of Urology, University College London Hospital, London, UK.
  • Eoin Dinneen
    Division of Surgery and Interventional Science, University College London, Charles Bell House, 43-45 Foley Street, Fitzrovia, London, W1W 7TS, UK. eoin.dinneen@nhs.net.
  • Tim Briggs
    Department of Urology and Division of Surgery and Interventional Science, University College London Hospital, London, UK.
  • Anand Kelkar
    Department of Urology, University College London Hospital, London, UK.
  • Prabhakar Rajan
    Department of Urology, University College London Hospital, London, UK.
  • Senthil Nathan
    Department of Urology and Division of Surgery and Interventional Science, University College London Hospital, London, UK.
  • John D Kelly
    Department of Urology and Division of Surgery and Interventional Science, University College London Hospital, London, UK.
  • Prasanna Sooriakumaran
    Department of Uro-oncology, University College London Hospitals NHS Foundation Trust.
  • Ashwin Sridhar
    Department of Urology and Division of Surgery and Interventional Science, University College London Hospital, London, UK.